Evidence map›Paper›PMID 35832260›Full record

ArticleSAGE open medicine2022

COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study.

Astawus Alemayehu, Abebaw Demissie, Mohammed Yusuf, Yasin Abdullahi, Remzia Abdulwehab, Lemessa Oljira, Dereje Feleke

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Self-reported side effects of COVID-19 vaccines among the public.Journal of pharmaceutical policy and practice · 2024
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Astawus AlemayehuDepartment of Nursing, Rift Valley University, Harar, Ethiopia.ORCID https://orcid.org/0000-0003-1384-7123
Abebaw DemissieDepartment of Nursing, Rift Valley University, Harar, Ethiopia.
Mohammed YusufDepartment of Nursing, Rift Valley University, Harar, Ethiopia.
Yasin AbdullahiDepartment of Management, Harar Health Science College, Harar, Ethiopia.
Remzia AbdulwehabDepartment of Public Health, Harar Health Science College, Harar, Ethiopia.ORCID https://orcid.org/0000-0001-7465-5622
Lemessa OljiraSchool of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Dereje FelekeDepartment of Health Informatics, Harar Health Science College, Harar, Ethiopia.
Haramaya University · ETRift Valley University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The pandemic of coronavirus disease 2019 (COVID-19) is a major threat to community health, and vaccinations are a safe and effective way to reduce disease loads around the world. This study aimed to assess the age and gender disparity in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia. Methods: A community-based cross-sectional study design was conducted among 832 randomly selected individuals from December 1st to 20th, 2021, in eastern Ethiopia. Data were collected by face-to-face interviews using a pretested structured questionnaire. Data were analyzed using the SPSS V26. Descriptive summary statistics were done. A chi-square test statistic was computed to assess the difference in adverse effects between age groups and both genders. Result: Out of 832 study participants who had taken the first dose of AstraZeneca vaccine, 96.3% of them felt at least one adverse effect. The magnitude of adverse reactions was higher among male participants. The reported adverse reactions were significantly higher in the age group of 50-60 years with comorbidity than those of <50 and >60 years of age. Conclusion: Overall, there is a significant age and gender difference in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine. In addition, adverse reactions were higher among people with comorbidity in the age group of 50-60 years. The Harari Regional Health Bureau should provide training for frontline healthcare workers on early recognition and response to adverse effects of the COVID-19 vaccine. In addition, information and education should be provided to the community as a whole regarding recognition and the appropriate measures to be taken.

Indexed as

adverse effectsage disparityCOVID-19 vaccinegender disparity

Identifiers

PMID35832260
PMCPMC9272167
OpenAlexW4285305927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.